35
Participants
Start Date
May 31, 2006
Primary Completion Date
March 31, 2009
Study Completion Date
August 31, 2012
Bevacizumab
Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
Gemcitabine
Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
Oxaliplatin
Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
Massachusetts General Hospital Cancer Center, Boston
Dana Farber Cancer Institute, Boston
Collaborators (2)
Genentech, Inc.
INDUSTRY
Sanofi
INDUSTRY
Beth Israel Deaconess Medical Center
OTHER
Brigham and Women's Hospital
OTHER
Dana-Farber Cancer Institute
OTHER
Massachusetts General Hospital
OTHER